Cardiovascular effects of glucagon-like peptide-1 receptor agonist therapies in patients with type 1 diabetes

Diabetes Obesity and Metabolism ◽

10.1111/dom.12883 ◽

2017 ◽

Vol 19 (5) ◽

pp. 613-614 ◽

Author(s):

Manfredi Rizzo ◽

Ali A. Rizvi ◽

Giorgio Sesti

Keyword(s):

Type 1 Diabetes ◽

Receptor Agonist ◽

Cardiovascular Effects ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Faculty Opinions recommendation of Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8727957.11798054 ◽

2011 ◽

Author(s):

Kyong Soo Park ◽

Soo Heon Kwak

Keyword(s):

Type 1 Diabetes ◽

Blood Glucose ◽

Blood Glucose Level ◽

Rat Model ◽

Renal Injury ◽

Receptor Agonist ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Inflammatory Action

Download Full-text

Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes

Diabetologia ◽

10.1007/s00125-010-2028-x ◽

2011 ◽

Vol 54 (4) ◽

pp. 965-978 ◽

Author(s):

R. Kodera ◽

K. Shikata ◽

H. U. Kataoka ◽

T. Takatsuka ◽

S. Miyamoto ◽

...

Keyword(s):

Type 1 Diabetes ◽

Blood Glucose ◽

Blood Glucose Level ◽

Rat Model ◽

Renal Injury ◽

Receptor Agonist ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Inflammatory Action

Download Full-text

Addition of glucagon‐like peptide‐1 receptor agonist therapy to insulin in C‐peptide‐positive patients with type 1 diabetes

Diabetes Obesity and Metabolism ◽

10.1111/dom.13609 ◽

2019 ◽

Vol 21 (4) ◽

pp. 1054-1057

Author(s):

Nitesh D. Kuhadiya ◽

Ben Prohaska ◽

Husam Ghanim ◽

Paresh Dandona

Keyword(s):

Type 1 Diabetes ◽

Receptor Agonist ◽

Agonist Therapy ◽

C Peptide ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Faculty Opinions recommendation of Glucagon-like peptide-1 receptor agonist ameliorates renal injury through its anti-inflammatory action without lowering blood glucose level in a rat model of type 1 diabetes.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.8727957.9242055 ◽

2011 ◽

Author(s):

Carolyn Ecelbarger

Keyword(s):

Type 1 Diabetes ◽

Blood Glucose ◽

Blood Glucose Level ◽

Rat Model ◽

Renal Injury ◽

Receptor Agonist ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Inflammatory Action

Download Full-text

Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: The Lira-1 study

BMJ Open ◽

10.1136/bmjopen-2015-007791 ◽

2015 ◽

Vol 5 (4) ◽

pp. e007791-e007791 ◽

Author(s):

T. F. Dejgaard ◽

F. K. Knop ◽

L. Tarnow ◽

C. S. Frandsen ◽

T. S. Hansen ◽

...

Keyword(s):

Type 1 Diabetes ◽

Insulin Therapy ◽

Receptor Agonist ◽

Controlled Study ◽

Efficacy And Safety ◽

Double Blind ◽

Double Blind Placebo ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Effects of Sodium-Glucose Cotransporter Inhibitor/Glucagon-Like Peptide-1 Receptor Agonist Add-On to Insulin Therapy on Glucose Homeostasis and Body Weight in Patients With Type 1 Diabetes: A Network Meta-Analysis

Frontiers in Endocrinology ◽

10.3389/fendo.2020.00553 ◽

2020 ◽

Vol 11 ◽

Author(s):

Yoon Ji Kim ◽

Seun Deuk Hwang ◽

Soo Lim

Keyword(s):

Type 1 Diabetes ◽

Body Weight ◽

Insulin Therapy ◽

Glucose Homeostasis ◽

Receptor Agonist ◽

Meta Analysis ◽

Sodium Glucose Cotransporter ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review

Diabetes Obesity and Metabolism ◽

10.1111/dom.12911 ◽

2017 ◽

Vol 19 (7) ◽

pp. 915-925 ◽

Author(s):

Anders Albèr ◽

Andreas Brønden ◽

Filip K. Knop

Keyword(s):

Type 1 Diabetes ◽

Insulin Therapy ◽

Short Acting ◽

Receptor Agonists ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Role of Glucagon-like peptide-1 “Liraglutide” in Management of Type 1 Diabetes

International Journal of Pharmaceutical and Phytopharmacological Research ◽

10.51847/skbdqro7ng ◽

2021 ◽

Vol 11 (1) ◽

pp. 89-93

Keyword(s):

Type 1 Diabetes ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Do glucagon-like peptide-1 receptor (GLP-1R) agonists have potential as adjuncts in the treatment of type 1 diabetes?

Expert Opinion on Pharmacotherapy ◽

10.1080/14656566.2018.1519547 ◽

2018 ◽

Vol 19 (15) ◽

pp. 1655-1661 ◽

Author(s):

Sheila A. Doggrell

Keyword(s):

Type 1 Diabetes ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text

Glucagon-like peptide 1 improved glycemic control in type 1 diabetes

BMC Endocrine Disorders ◽

10.1186/1472-6823-3-3 ◽

2003 ◽

Vol 3 (1) ◽

Author(s):

Margaret T Behme ◽

John Dupré ◽

Thomas J McDonald

Keyword(s):

Type 1 Diabetes ◽

Glycemic Control ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1

Download Full-text